Bone Biologics Stock (NASDAQ:BBLG)
Previous Close
$1.24
52W Range
$1.00 - $10.56
50D Avg
$1.50
200D Avg
$2.41
Market Cap
$2.14M
Avg Vol (3M)
$2.16M
Beta
0.67
Div Yield
-
BBLG Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
BBLG Performance
Peer Comparison
Ticker | Company |
---|---|
TLIS | Talis Biomedical Corporation |
RPID | Rapid Micro Biosystems, Inc. |
INVO | INVO Bioscience, Inc. |
TIVC | Tivic Health Systems, Inc. |
NUWE | Nuwellis, Inc. |
RSLS | ReShape Lifesciences Inc. |
BJDX | Bluejay Diagnostics, Inc. |
HSCS | Heart Test Laboratories, Inc. |
MOTS | Motus GI Holdings, Inc. |
TNON | Tenon Medical, Inc. |
SINT | Sintx Technologies, Inc. |
VVOS | Vivos Therapeutics, Inc. |
NAOV | NanoVibronix, Inc. |